Ligand buys future Selexis royalties
This article was originally published in Scrip
Executive Summary
San Diego-based Ligand Pharmaceuticals bought the rights to future milestone and royalty payments for more than 15 biologic development programs from Selexis to access the private Swiss firm's underlying technology and broaden Ligand's portfolio beyond small molecules.